 Phosphatidylinositol 3-Kinases
"Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
| Descriptor ID |
D019869
|
| MeSH Number(s) |
D08.811.913.696.620.500
|
| Concept/Terms |
Phosphatidylinositol 3-Kinases- Phosphatidylinositol 3-Kinases
- Phosphatidylinositol 3 Kinases
- Phosphoinositide 3-Hydroxykinase
- PI 3-Kinase
- PtdIns 3-Kinases
- 3-Kinases, PtdIns
- PtdIns 3 Kinases
- PI-3K
- PI3 Kinases
- Kinases, PI3
- PI3-Kinase
- PtdIns 3-Kinase
- Phosphatidylinositol-3-OH Kinase
- PI-3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 4 | 5 | | 2000 | 2 | 2 | 4 | | 2001 | 4 | 2 | 6 | | 2002 | 1 | 2 | 3 | | 2003 | 3 | 4 | 7 | | 2004 | 6 | 6 | 12 | | 2005 | 2 | 5 | 7 | | 2006 | 4 | 7 | 11 | | 2007 | 5 | 6 | 11 | | 2008 | 7 | 6 | 13 | | 2009 | 7 | 2 | 9 | | 2010 | 5 | 8 | 13 | | 2011 | 1 | 9 | 10 | | 2012 | 4 | 8 | 12 | | 2013 | 6 | 10 | 16 | | 2014 | 3 | 11 | 14 | | 2015 | 2 | 9 | 11 | | 2016 | 4 | 7 | 11 | | 2017 | 3 | 9 | 12 | | 2018 | 2 | 4 | 6 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 3 | 6 | | 2021 | 0 | 1 | 1 | | 2022 | 2 | 13 | 15 | | 2023 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Unali G, Crivicich G, Pagani I, Abou-Alezz M, Folchini F, Valeri E, Matafora V, Reisz JA, Giordano AMS, Cuccovillo I, Butta GM, Donnici L, D'Alessandro A, De Francesco R, Manganaro L, Cittaro D, Merelli I, Petrillo C, Bachi A, Vicenzi E, Kajaste-Rudnitski A. Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. EMBO J. 2023 May 15; 42(10):e112234.
-
Wang S, Rong R, Yang DM, Fujimoto J, Bishop JA, Yan S, Cai L, Behrens C, Berry LD, Wilhelm C, Aisner D, Sholl L, Johnson BE, Kwiatkowski DJ, Wistuba II, Bunn PA, Minna J, Xiao G, Kris MG, Xie Y. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023 01 17; 133(2).
-
McCaleb MR, Miranda AM, Ratliff KC, Torres RM, Pelanda R. CD19 Is Internalized Together with IgM in Proportion to B Cell Receptor Stimulation and Is Modulated by Phosphatidylinositol 3-Kinase in Bone Marrow Immature B Cells. Immunohorizons. 2023 01 01; 7(1):49-63.
-
Fleming IR, Hannan JP, Swisher GH, Tesdahl CD, Martyr JG, Cordaro NJ, Erbse AH, Falke JJ. Binding of active Ras and its mutants to the Ras binding domain of PI-3-kinase: A quantitative approach to KD measurements. Anal Biochem. 2023 02 15; 663:115019.
-
Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 03; 26(1):188-193.
-
Harrison D, Gill J, Roth M, Hingorani P, Zhang W, Teicher B, Earley E, Erickson S, Gatto G, Kumasheva R, Houghton P, Smith M, Anders Kolb E, Gorlick R. Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatr Blood Cancer. 2023 Jan; 70(1):e30017.
-
El-Khouly OA, Henen MA, El-Sayed MA, El-Messery SM. Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer. Sci Rep. 2022 Oct 12; 12(1):17104.
-
Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 09 06; 21(9):1381-1392.
-
Lai D, Gade M, Yang E, Koh HY, Lu J, Walley NM, Buckley AF, Sands TT, Akman CI, Mikati MA, McKhann GM, Goldman JE, Canoll P, Alexander AL, Park KL, Von Allmen GK, Rodziyevska O, Bhattacharjee MB, Lidov HGW, Vogel H, Grant GA, Porter BE, Poduri AH, Crino PB, Heinzen EL. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations. Brain. 2022 08 27; 145(8):2704-2720.
-
Kelly AC, J Rosario F, Chan J, Cox LA, Powell TL, Jansson T. Transcriptomic responses are sex-dependent in the skeletal muscle and liver in offspring of obese mice. Am J Physiol Endocrinol Metab. 2022 10 01; 323(4):E336-E353.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|